Busyamas Chewaskulyong

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Tony Mok, Yi‐Long Wu, Sumitra Thongprasert et al. · New England Journal of Medicine · 2009 · 8.2K citations · Full text

Medicine, Oncology, Pharmacology +13

Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer

Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste et al. · New England Journal of Medicine · 2017 · 5.3K citations · Full text

Medicine, Oncology, Pharmacology +16

Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC

Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard et al. · New England Journal of Medicine · 2019 · 2.8K citations · Full text

Medicine, Oncology, Pharmacology +17

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 576 citations · Full text

Medicine, Oncology, Pharmacology +8

CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer

Pasi A. Jänne, David Planchard, Kunihiko Kobayashi et al. · Journal of Clinical Oncology · 2023 · 125 citations · Full text

Medicine, Oncology, Pharmacology +11